MedPath

Prospective observational study of anti-PD-L1 antibody drug atezolizumab for non small cell lung cancer

Not Applicable
Recruiting
Conditions
non small cell lung cancer
Registration Number
JPRN-UMIN000035616
Lead Sponsor
Second division, Depertment of Internal Medicine, Hamamatsu University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients with autoimmune diseases or recurrent autoimmune disease 2. Patient with interstitial pneumonia 3. Patients with serious complications 4. Patients with difficult-to-control central nervous lesions

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath